Factor IX

Adult: As treatment and control of bleeding episodes: Dosage is individualised based on the severity of factor IX deficiency, extent and location of bleeding, and patient's clinical response. Recommended target factor IX concentrations: Early haemarthrosis, muscle or oral bleeding: Increase to 20-40% of normal; doses are given 24 hourly and continued for at least 1 day until the bleeding episode (as indicated by pain) is resolved or healing is achieved. More extensive haemarthrosis, muscle bleeding or haematoma: Increase to 30-60% of normal; doses are given 24 hourly for 3-4 days or more until pain and acute disability are resolved. Life-threatening haemorrhages: Increase to 60-100% of normal; doses are given 8-24 hourly until threat is resolved. Minor surgery including tooth extraction: Increase to 30-60% of normal; doses are given 24 hourly and continued for at least 1 day until healing is obtained. Major surgery (pre-operative and post-operative): Increase to 80-100% of normal; doses are given 8-24 hourly until adequate wound healing, then continue therapy for at least another 7 days to maintain a factor IX activity of 30-60%. As long-term prophylaxis against bleeding in severe cases: 20-40 international units/kg at intervals of 3-4 days. Dosing recommendations may vary among individual products and between countries. Refer to specific product or local treatment guidelines for further information.